Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice.
J Am Coll Cardiol
; 82(4): 281-291, 2023 07 25.
Article
em En
| MEDLINE
| ID: mdl-37207923
ABSTRACT
BACKGROUND:
Severe tricuspid regurgitation (TR) is known to be associated with substantial morbidity and mortality.OBJECTIVES:
The authors sought to study the acute outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair with the TriClip system (Abbott) in a contemporary, real-world setting.METHODS:
The bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device) postapproval study is a prospective, single-arm, open-label, multicenter, postmarket registry conducted at 26 sites in Europe. Echocardiographic assessment was performed at a core laboratory.RESULTS:
Enrolled subjects were elderly (79 ± 7 years of age) with significant comorbidities. Eighty-eight percent had baseline massive or torrential TR, and 80% of subjects were in NYHA functional class III or IV. Successful device implantation occurred in 99% of subjects, and TR was reduced to ≤moderate at 30 days in 77%. Associated significant improvements in NYHA functional class (I/II, 20% to 79%; P < 0.0001) and Kansas City Cardiomyopathy Questionnaire score (19 ± 23 points improvement; P < 0.0001) were observed at 30 days. With baseline TR grade removed as a variable, smaller right atrial volume and smaller tethering distance at baseline were independent predictors of TR reduction to ≤moderate at discharge (OR 0.679; 95% CI 0.537-0.858; P = 0.0012; OR 0.722; 95% CI 0.564-0.924; P = 0.0097). Fourteen subjects (2.5%) experienced a major adverse event at 30 days.CONCLUSIONS:
Transcatheter tricuspid valve repair was found to be safe and effective in treating significant TR in a diverse, real-world population. (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device [bRIGHT]; NCT04483089).Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Insuficiência da Valva Tricúspide
/
Implante de Prótese de Valva Cardíaca
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article